News and Trends 2 May 2019 Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a key disease biomarker in a phase II trial, but showed potential for reducing liver scarring. Primary biliary cholangitis is an autoimmune disease that damages the liver and can lead to liver scarring (fibrosis) or the […] May 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2018 Solid Phase II Performance for French Autoimmune Liver Disease Drug Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […] November 7, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2017 This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC. Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2 diabetes and kidney disease. The French biotech has […] June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […] May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 French Biotech gets a Second Opportunity to Fight Liver Fibrosis Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […] May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email